T cell activation markers and African mitochondrial DNA Haplogroups among non-hispanic black participants in AIDS clinical trials group study 384

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hulgan, Todd ^a   Robbins, Gregory K ^b   Kalams, Spyros A ^a   Samuels, David C ^a   Grady, Benjamin ^a   Shafer, Robert ^c   Murdock, Deborah G ^a   Selph, Doug ^a   Haas, David W ^a   Pollard, Richard B ^d   de Gruttola, Victor ^e   Snyder, Sally ^p   Nevin, Thomas ^f   Pettinelli, Carla ^g   Dube, Michael ^h   Fischl, Margaret ⁱ   Delaphna, Robert ^j   Gideon, Linda ^k   D'Aquila, Richard ^l   Vella, Stefano ^m   Merigan, Thomas ⁿ   Hirsch, Martin ^o   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ MIAMI UNIVERSITY   (United States)

^j HOWARD UNIVERSITY   (United States)

^k Frontier Science and Technology Foundation   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁿ STANFORD UNIVERSITY   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA; NELFINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CD4-CD8 RATIO; DNA, MITOCHONDRIAL; FEMALE; GENE FREQUENCY; HAPLOTYPES; HIV-1; HUMANS; LINEAR MODELS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84865433650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043803     Document Type: Article

References (61)

1. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
2. Gutierrez F, Padilla S, Masia M, Iribarren JA, Moreno S, et al. (2006) Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 1: e89.
3. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G, (2009) The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 48: 328-337.
4. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401-410.
5. Rigato PO, Hong MA, Casseb J, Ueda M, de Castro I, et al. (2008) Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3′A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms. Curr HIV Res 6: 466-473.
6. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, et al. (2008) CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 14: 413-420.
7. Rauch A, Nolan D, Furrer H, McKinnon E, John M, et al. (2008) HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 46: 1921-1925.
8. Soria A, Guerini FR, Bandera A, Bolognesi E, Uglietti A, et al. (2011) KIR-HLA Genotypes in HIV-Infected Patients Lacking Immunological Recovery despite Effective Antiretroviral Therapy. PLoS One 6: e27349.
9. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, et al. (2006) Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis 194: 1098-1107.
10. Nasi M, Pinti M, Bugarini R, Troiano L, Lugli E, et al. (2005) Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 57: 628-635.
11. Varbanov M, Espert L, Biard-Piechaczyk M, (2006) Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Rev 8: 221-236.
12. Petit F, Arnoult D, Viollet L, Estaquier J, (2003) Intrinsic and extrinsic pathways signaling during HIV-1 mediated cell death. Biochimie 85: 795-811.
13. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543.
14. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
15. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, et al. (2006) Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 194: 29-37.
16. Massanella M, Negredo E, Perez-Alvarez N, Puig J, Ruiz-Hernandez R, et al. (2010) CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24: 959-968.
17. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, et al. (2006) Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 42: 426-434.
18. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, et al. (1996) Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 156: 3509-3520.
19. Groux H, Torpier G, Monte D, Mouton Y, Capron A, et al. (1992) Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 175: 331-340.
20. Gougeon ML, Piacentini M, (2009) New insights on the role of apoptosis and autophagy in HIV pathogenesis. Apoptosis 14: 501-508.
21. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, et al. (2011) High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 11: 43.
22. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48: 350-361.
23. Bouillet P, O'Reilly LA, (2009) CD95, BIM and T cell homeostasis. Nat Rev Immunol 9: 514-519.
24. Grimaldi M, Denizot M, Espert L, Robert-Hebmann V, Biard-Piechaczyk M, (2005) Mitochondria-dependent apoptosis in T-cell homeostasis. Curr Opin Investig Drugs 6: 1095-1102.
25. Negredo E, Massanella M, Puig J, Perez-Alvarez N, Gallego-Escuredo JM, et al. (2010) Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 50: 1300-1308.
26. Badley AD, Roumier T, Lum JJ, Kroemer G, (2003) Mitochondrion-mediated apoptosis in HIV-1 infection. Trends Pharmacol Sci 24: 298-305.
27. Chavan SJ, Tamma SL, Kaplan M, Gersten M, Pahwa SG, (1999) Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol 93: 24-33.
28. Johnson N, Parkin JM, (1998) Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis. Clin Exp Immunol 113: 229-234.
29. Wallace DC, Brown MD, Lott MT, (1999) Mitochondrial DNA variation in human evolution and disease. Gene 238: 211-230.
30. Gomez-Duran A, Pacheu-Grau D, Lopez-Gallardo E, Diez-Sanchez C, Montoya J, et al. (2010) Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum Mol Genet 19: 3343-3353.
31. Brown MD, Trounce IA, Jun AS, Allen JC, Wallace DC, (2000) Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation. J Biol Chem 275: 39831-39836.
32. De Benedictis G, Rose G, Carrieri G, De Luca M, Falcone E, et al. (1999) Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J 13: 1532.
33. Mancuso M, Filosto M, Orsucci D, Siciliano G, (2008) Mitochondrial DNA sequence variation and neurodegeneration. Hum Genomics 3: 71-78.
34. Nishigaki Y, Fuku N, Tanaka M, (2010) Mitochondrial haplogroups associated with lifestyle-related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 (Suppl 1):: S221-235.
35. Raule N, Sevini F, Santoro A, Altilia S, Franceschi C, (2007) Association studies on human mitochondrial DNA: methodological aspects and results in the most common age-related diseases. Mitochondrion 7: 29-38.
36. Casula M, Vrisekoop N, Wit FW, de Baar MP, de Ronde A, et al. (2007) Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation. J Infect Dis 196: 371-376.
37. Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN, (2006) Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med 7: 53-58.
38. Hendrickson SL, Hutcheson HB, Ruiz-Pesini E, Poole JC, Lautenberger J, et al. (2008) Mitochondrial DNA haplogroups influence AIDS progression. AIDS 22: 2429-2439.
39. Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, et al. (2011) Mitochondrial Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy Initiation in AIDS Clinical Trials Group Study 384. J Acquir Immune Defic Syndr 58: 363-370.
40. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2293-2303.
41. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, et al. (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2304-2315.
42. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, et al. (2003) A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 4: 287-300.
43. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, et al. (2005) Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. Aids 19: 1341-1349.
44. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, et al. (2006) Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Aids 20: 1503-1513.
45. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, et al. (2006) Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics 16: 837-845.
46. Maitra A, Cohen Y, Gillespie SE, Mambo E, Fukushima N, et al. (2004) The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 14: 812-819.
47. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, et al. (1999) Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23: 147.
48. Herrnstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, et al. (2002) Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet 70: 1152-1171.
49. Garg H, Blumenthal R, (2006) HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 79: 351-362.
50. Peraire J, Miro O, Saumoy M, Domingo P, Pedrol E, et al. (2007) HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr HIV Res 5: 467-473.
51. Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, et al. (2003) Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 70: 497-505.
52. Sternfeld T, Schmid M, Tischleder A, Mudra S, Schlamp A, et al. (2007) The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells. Antivir Ther 12: 769-778.
53. Sternfeld T, Tischleder A, Schuster M, Bogner JR, (2009) Mitochondrial membrane potential and apoptosis of blood mononuclear cells in untreated HIV-1 infected patients. HIV Med 10: 512-519.
54. Karamchand L, Dawood H, Chuturgoon AA, (2008) Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients. J Acquir Immune Defic Syndr 48: 381-388.
55. Quintana A, Pasche M, Junker C, Al-Ansary D, Rieger H, et al. (2011) Calcium microdomains at the immunological synapse: how ORAI channels, mitochondria and calcium pumps generate local calcium signals for efficient T-cell activation. EMBO J 30: 3895-3912.
56. Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, et al. (2007) T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A 104: 14418-14423.
57. Wang J, Silva JP, Gustafsson CM, Rustin P, Larsson NG, (2001) Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci U S A 98: 4038-4043.
58. Mirabella M, Di Giovanni S, Silvestri G, Tonali P, Servidei S, (2000) Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 123 (Pt 1): 93-104.
59. Geromel V, Kadhom N, Cebalos-Picot I, Ouari O, Polidori A, et al. (2001) Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene of the mitochondrial DNA. Hum Mol Genet 10: 1221-1228.
60. Nasi M, Guaraldi G, Orlando G, Durante C, Pinti M, et al. (2008) Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy-Related Lipodystrophy. Clin Infect Dis 47: 962-968.
61. Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, et al. (2011) Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 80: 42-49.